Amy Billett MD
Amy Billett’s personal passion is to improve the quality and safety of pediatric health care by making it easier for health care workers, patients and families to do their “jobs” better. She has focused on improving systems of care to maximize safety and quality since 1998, including multiple efforts improving chemotherapy safety.
She served the Nemours/Alfred I. duPont Hospital for Children as the institution’s first Chief Quality and Safety Officer for three years. During her previous 30 years in Boston, she had multiple roles including practicing pediatric hematology/oncology at Dana-Farber Boston Children’s Center for Cancer and Blood Disorders, training and mentoring more than 100 fellows in Pediatric Hematology/Oncology and more recently Clinical Informatics, co-leading implementation of multiple vendor electronic health record projects, and leading quality and safety for the pediatric hematology/oncology service line across three institutions.
Dr. Billett is a magna cum laude graduate of Yale University, earning her B.S. with distinction in Biology, she went on to receive her M.D. from Harvard Medical School. She completed her post-doctoral internship and residency in Pediatrics at the University of Washington Affiliated Hospitals in Seattle, and her fellowship in Pediatric Hematology/Oncology at Children’s Hospital and Dana-Farber Cancer Institute in Boston. She completed her training, with academic appointments at Harvard Medical School and hospital appointments in Pediatric Hematology/Oncology at the Dana-Farber Cancer Institute, Boston Children’s Hospital, and Brigham and Women’s Hospital. Dr. Billett has served in leadership roles on a number of national committees and organizations, including President of the American Society of Pediatric Hematology/Oncology; and she has presented nationally and internationally on patient safety and quality.
She was a founding faculty member of the Childhood Cancer and Blood Disorders Network, a national quality improvement collaborative, that successfully reduced inpatient catheter-associated bloodstream infections by 30% in pediatric hematology/oncology inpatients. She led “Team Line” at Dana Farber/Boston Children’s which pioneered the development of a patient/family learning curriculum to ensure optimal line care in the home and prevent ambulatory catheter-associated blood stream infections. Amy has served on the American Society of Clinical Oncology chemotherapy safety standards working group, the American Society of Pediatric Hematology/Oncology Leadership Development taskforce, the Solutions for Patient Safety Ambulatory Foundations taskforce and is currently a member of the American Society of Hematology Committee on Quality.